Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| CJIP101025 | — | — | Freedom Diagnostics | Endotoxin | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. CJC-1295 is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Orbitrex Peptides sell CJC-1295?
Orbitrex Peptides has 1 COA on file for CJC-1295 but no active price listing is currently tracked.
Is Orbitrex Peptides's CJC-1295 third-party tested?
Yes — Disclosed Labs has indexed 1 Certificate of Analysis for Orbitrex Peptides's CJC-1295. Orbitrex Peptides holds an overall trust grade of A (92/100) across all 164 COAs on file.
What is Orbitrex Peptides's trust grade for CJC-1295?
Orbitrex Peptides has an overall Disclosed Labs trust grade of A (92/100), computed from 164 COAs across all peptides. The most recent CJC-1295 COA was issued by Freedom Diagnostics.
Where is the cheapest CJC-1295?
As of the latest data, Peptide Supply Co. offers CJC-1295 at $3.80/mg — compare with Orbitrex Peptides's listing. See the full CJC-1295 price comparison.
Is CJC-1295 legal to buy?
CJC-1295 is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
Disclosed Labs